AZD4512

AZD4512 is an antibody-drug conjugate developed by AstraZeneca. Its target is CD22 (the sponsor names CD22). The sponsor states: An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page. ClinicalTrials.gov describes the intervention as: AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07123454, plans to enrol 91 participants with primary completion expected 2028-03-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.